Summary
DEXCOM INC (DXCM) filed an 8-K on December 17, 2021, to report on compensatory arrangements for its executive officers. The Compensation Committee approved grants of Restricted Stock Units (RSUs) to key executives, specifically the EVP, Chief Technology Officer and the EVP, Chief Financial Officer. These grants are intended to incentivize employee retention and align executive interests with long-term company performance.
Key Highlights
- 1DexCom granted RSUs to two named executive officers on December 15, 2021.
- 2The recipients of the RSU grants are Jacob Leach (EVP, Chief Technology Officer) and Jereme Sylvain (EVP, Chief Financial Officer).
- 3Each executive officer received 2,925 RSUs.
- 4The RSUs are granted under the Company's Amended and Restated 2015 Equity Incentive Plan.
- 5Vesting begins on the grant date, with 50% vesting on December 15, 2023.
- 6The remaining 50% vests in tranches of 12.5% on March 8, June 8, September 8, and December 15, 2024.
- 7Continued service with the company is a condition for vesting.
Frequently Asked Questions
The primary purpose of these RSU grants is to incentivize employee retention and ensure that key executives remain with DexCom over the long term. This also aligns their interests with the company's continued success.
The RSUs will vest over time. A significant portion (50%) will vest on December 15, 2023, with the remainder vesting in smaller installments throughout 2024. Continued employment is required for vesting.
A total of 5,850 RSUs were granted, with each of the two named executive officers receiving 2,925 RSUs.